Research progress on gene mutations and drug resistance in leukemia
Drug Resistance Updates · 2025-03 · 79 · 101195
DOI: 10.1016/j.drup.2024.101195 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Drug Resistance Updates, 2025-03. Verfasst von Xiangyu Ma und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, 100045, China. Hauptthemen laut MEDLINE: Drug Resistance, Neoplasm, Leukemia, Mutation, Antineoplastic Agents. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 345 Literaturangaben. Gefördert von: Peking University Third Hospital, National Natural Science Foundation of China.
Abstract (Originalsprache)
Leukemia is a type of blood cancer characterized by the uncontrolled growth of abnormal cells in the bone marrow, which replace normal blood cells and disrupt normal blood cell function. Timely and personalized interventions are crucial for disease management and improving survival rates. However, many patients experience relapse following conventional chemotherapy, and increasing treatment intensity often fails to improve outcomes due to mutated gene-induced drug resistance in leukemia cells. This article analyzes the association of gene mutations and drug resistance in leukemia. It explores genetic abnormalities in leukemia, highlighting recently identified mutations affecting signaling pathways, cell apoptosis, epigenetic regulation, histone modification, and splicing mechanisms. Additionally, the article discusses therapeutic strategies such as molecular targeting of gene mutations, alternative pathway targeting, and immunotherapy in leukemia. These approaches aim to combat specific drug-resistant mutations, providing potential avenues to mitigate leukemia relapse. Future research with these strategies holds promise for advancing leukemia treatment and addressing the challenges of drug-resistant mutations to improve patient outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, 100045, China.
- Department of Pharmacy, Peking University Third Hospital, Beijing 100191, China.
- Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John's University, New York, NY 11439, USA.
- Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John's University, New York, NY 11439, USA. Electronic address: chenz@stjohns.edu.
- Department of Pharmacy, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, 100045, China; Department of Pharmacy, Peking University Third Hospital, Beijing 100191, China. Ele…
Förderung
- Peking University Third Hospital
- National Natural Science Foundation of China
Zitieren
APA
Ma, X., Xu, J., Wang, Y., Fleishman, J. S., Bing, H., Yu, B., Li, Y., Bo, L., Zhang, S., Chen, Z. S., & Zhao, L. (2025). Research progress on gene mutations and drug resistance in leukemia. Drug Resistance Updates, 79, 101195. https://doi.org/10.1016/j.drup.2024.101195
Vancouver
Ma X, Xu J, Wang Y, Fleishman JS, Bing H, Yu B, et al. Research progress on gene mutations and drug resistance in leukemia. Drug Resistance Updates. 2025;79:101195. doi:10.1016/j.drup.2024.101195
BibTeX
@article{Ma2025,
author = {Ma, Xiangyu and Xu, Jiamin and Wang, Yanan and Fleishman, Joshua S and Bing, Hao and Yu, Boran and Li, Yanming and Bo, Letao and Zhang, Shaolong and Chen, Zhe-Sheng and Zhao, Libo},
title = {Research progress on gene mutations and drug resistance in leukemia},
journal = {Drug Resistance Updates},
year = {2025},
volume = {79},
pages = {101195},
doi = {10.1016/j.drup.2024.101195}
}
EUVIMED